| Company Name: |
Lynnchem |
| Tel: |
86-(0)29-85992781 17792393971 |
| Email: |
info@lynnchem.com |
| Company Name: |
Novachemistry |
| Tel: |
44-20819178-90 02081917890 |
| Email: |
info@novachemistry.com |
Relamorelin manufacturers
- Relamorelin
-
- $497.00
-
2026-05-11
- CAS:661472-41-9
- Purity: 99.26%
- Supply Ability: 10g
|
| | Relamorelin Basic information |
| Product Name: | Relamorelin | | Synonyms: | Relamorelin;4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophen-3-yl)-2-(piperidine-3-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide;4-Piperidinecarboxamide, 3-benzo[b]thien-3-yl-N-(4-piperidinylcarbonyl)-D-alanyl-D-tryptophyl-L-phenylalanyl-4-amino-;BIM 28131;BIM 28163;BIM28131;BIM-28131;BIM28163 | | CAS: | 661472-41-9 | | MF: | C43H50N8O5S | | MW: | 790.98 | | EINECS: | | | Product Categories: | | | Mol File: | 661472-41-9.mol |  |
| | Relamorelin Chemical Properties |
| Boiling point | 1216.171±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.361±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.858±0.20(predicted) |
| | Relamorelin Usage And Synthesis |
| Uses | Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research[1][2][3][4]. | | in vivo | Relamorelin (RM-131; 50-500 nmol/kg/day; s.c.; continuous infusion for 5 days) decreases the loss of body mass and fat mass. Relamorelin (500 nmol/kg/day; continuous infusion for 5 days) increases the food intake and weight gain in rats[1].
RM-131 (250-500nmol/kg; a single s.c.) stimulates acute food intake in wt but not growth hormone secretagogue receptor (GHR) ko mice[2]. | Animal Model: | F344/NTacfBR male rats implanted with tumor[1] | | Dosage: | 50, 500 nmol/kg/day | | Administration: | SC; continuous infusion at a rate of 0.5 μL/h for 5 d | | Result: | Resulted in an increase in food intake (tumor/saline 41.4 g, tumor/BIM-28131 72.5 g) and weight gain (tumor/saline -10.3%, tumor/BIM-28131 +19.5%).
|
| | References | [1] DeBoer MD, et, al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007 Jun;148(6):3004-12. DOI:10.1210/en.2007-0016
[2] Fischer K, et, al. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Front Nutr. 2015 Jan 12;1:31. DOI:10.3389/fnut.2014.00031
[3] Zatorski H, et, al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017 Dec;68(6):797-805. PMID:29550791
[4] Matthew Heckroth, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021 Apr 1;55(4):279-299. DOI:10.1097/MCG.0000000000001485
[5] Victor Chedid, et al. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017 Oct;26(10):1189-1197. DOI:10.1080/13543784.2017.1373088 |
| | Relamorelin Preparation Products And Raw materials |
|